News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Start News Corporate Action

Press releases

Regulatory

May 31, 2022

Change in the number of shares and votes in Egetis Therapeutics

Regulatory

May 19, 2022

Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue

Regulatory

April 28, 2022

Egetis Therapeutics publishes prospectus relating to the Rights Issue

Regulatory

March 21, 2022

Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million

February 10, 2021

Aladote presented as a novel emerging treatment of paracetamol overdose at two scientific conferences.

Regulatory

December 30, 2020

Change in the number of shares and votes in Egetis Therapeutics

Regulatory

November 30, 2020

Change in the number of shares and votes in PledPharma

Regulatory

November 25, 2020

PledPharma raises SEK 250 million in oversubscribed rights issue and utilized overallotment option

November 18, 2020

FDA grants Rare Pediatric Disease designation to Emcitate®

Regulatory

November 12, 2020

PledPharma publishes a supplement to the prospectus

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com